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ABSTRACT  
 
α-Methylacyl-CoA racemase (AMACR; P504S) is a promising novel drug target for prostate and other cancers. Assaying 
enzyme activity is difficult due to the reversibility of the ‘racemisation’ reaction and the difficulties in the separation of 
epimeric products; consequently few inhibitors have been described and no structure–activity relationship study has been 
performed. This paper describes the first structure–activity relationship study, in which a series of 23 known and potential 
rational AMACR inhibitors were evaluated. AMACR was potently inhibited (IC50 = 400–750 nM) by ibuprofenoyl-CoA and 
derivatives. Potency was positively correlated with inhibitor lipophilicity. AMACR was also inhibited by straight-chain and 
branched-chain acyl-CoA esters, with potency positively correlating with inhibitor lipophilicity. 2-Methyldecanoyl-CoAs 
were ca. 3-fold more potent inhibitors than decanoyl-CoA, demonstrating the importance of the 2-methyl group for effective 
inhibition. Elimination substrates and compounds with modified acyl-CoA cores were also investigated, and shown to be 
potent inhibitors. These results are the first to demonstrate structure–activity relationships of rational AMACR inhibitors and 
that potency can be predicted by acyl-CoA lipophilicity. The study also demonstrates the utility of the colorimetric assay for 
thorough inhibitor characterisation.  
 
 
 
 
1. Introduction 
 
Branched-chain fatty acids (e.g. phytanic acid pristanic acids) are 
common components of the human diet, and derivatives of such com-pounds 
are used as drug molecules e.g. ibuprofen [1,2]. Degradation of branched-
chain fatty acids occurs as the acyl-CoA ester, and the acyl-CoA oxidases and 
other enzymes involved in β-oxidation have an ab-solute requirement for S-2-
methylacyl-CoAs [3–5]. However, R-2-me-thylacyl-CoAs are produced from 
dietary and endogenous fatty acids and these cannot be immediately degraded 
by β-oxidation. The enzyme α-methylacyl-CoA racemase [1,2] (AMACR; 
P504S; E.C. 5.1.99.4) cat-alyses conversion of R-2-methylacyl-CoAs to a 
near 1:1 epimeric mix-ture [6,7] by a deprotonation/reprotonation reaction 
[7,8], probably via an enolate intermediate [9] (this reaction is referred to as 
“race-misation” [10]). The resulting S-2-methylacyl-CoAs are degraded by β-
oxidation whilst the 2R epimers are further processed to the 2S epimers by 
AMACR [1,2]. AMACR also plays a key role in the in vivo pharma-cological 
activation of R-ibuprofen by conversion to S-ibuprofen, via the corresponding 
acyl-CoA esters [1,2,11]. The S-ibuprofen resulting from this pathway exerts 
its anti-inflammatory effect by inhibiting 
 
 
 
 
 
cyclooxygenase-1 and -2 [12].  
AMACR protein levels are increased in prostate [13,14] and several other 
cancers [1,15–18]. Catalytic activity of AMACR is increased by 4-to 10-fold 
in prostate cancer cells [19,20], with the AMACR 1A splice variant [1,2,21–
24] (possessing “racemase” activity [7,10]) showing the most significant 
increase in expression [19,20]. Reducing AMACR 1A levels using siRNA or 
shRNA approaches [19,25,26] has been shown to reduce proliferation of 
prostate cancer cells via a pathway which is synergistic with the use of an 
androgen receptor antagonist, studies which have validated AMACR 1A as a 
chemotherapeutic target. Some advanced prostate cancer cell lines revert from 
castrate-resistant (a.k.a. androgen-independent) growth to androgen-
dependent growth upon knockdown of AMACR 1A [26]. Consequently, 
AMACR has attracted considerable interest as a prostate cancer biomarker 
[1,2,27] and drug target [25,28–31]. However, the lack of a convenient assay 
to measure AMACR activity [32,33] has severely hampered the development 
of AMACR inhibitors as new chemotherapeutic drugs against cancers that 
over-express AMACR, and consequently only a few rationally designed 
inhibitors of AMACR [28–30,34] or MCR [31,35] (M. tuberculosis 
homologue) have been reported. No systematic study of AMACR 
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Scheme 1. The colorimetric assay for AMACR 1A  
[32] showing elimination of 2,4-dinitrophenolate 2.  
 
 
 
 
 
 
inhibitor SAR has been undertaken [32,33].  
Recently, we reported a versatile continuous assay for AMACR based on 
the utilisation of our novel substrate 1 that can eliminate 2,4-dinitrophenolate 
2, which can be monitored by absorbance at 354 nm, and unsaturated product 
3 (Scheme 1). This new assay [32] was used to examine the potency of two 
known acyl-CoA inhibitors (N-dodecyl-N-methylcarbamoyl-CoA 4 [29] and 
ibuprofenoyl-CoA 5 [6]; Fig. 1) and selected known non-specific protein-
modification agents [25]. This paper reports the first systematic examination 
of SAR for rationally designed acyl-CoA inhibitors of AMACR. Compounds 
investigated (Fig. 1) include those with aromatic side-chains, (5–11); 
Straight-chain acyl-CoA esters (12–17); Branched-chain substrates (18–21) 
and pro-duct 22. Analogues of known inhibitors with modified 2-methylacyl-
CoA moieties (4, 23–26) were also examined. The results reveal a correlation 
between potency and lipophilicity of the inhibitors, con-sistent with 
observations on MCR inhibitors [35], the homologous en-zyme from M. 
tuberculosis. 
 
 
2. Results and discussion 
 
AMACR is a promising novel cancer drug target, but therapeutic 
development in this field has been slow due to the lack of a robust enzyme 
assay. Thus, the majority of studies reporting AMACR in-hibitors have 
largely focussed on rationally designed drugs [28–30,32,33]. In most cases, 
only one or a few examples of each in-hibitor type has been evaluated, and no 
systematic SAR study has been performed. Initial SAR studies have been 
carried out on reversible [31] and irreversible [35] inhibitors of MCR (the M. 
tuberculosis homologue). In addition, different research groups have used 
different assays during their studies, making it difficult to compare results 
directly. In this study, the SAR of rational AMACR inhibitors were explored 
using a series of acyl-CoA esters (Fig. 1). These included compounds 
previously tested as substrates (5–11 [6,11]; 12–17 [36]; 18–20, 22 [7,10]). 
Most of these compounds have not been tested as inhibitors with the ex-
ception of 5 [28,32,37,38] and 13, 15–17 (which were previously re-ported 
to be inactive [37,38]). Compound 21 was included as an epimer of 20, and 
has not been previously reported as a substrate or inhibitor (although the 3-
fluoro-2-methylhexadecanoyl-CoA analogues are po-tent inhibitors [28]). 
Compound 24 is a synthetic intermediate to 25, and has not been previously 
tested as a substrate or inhibitor. Com-pounds 22, 25 and 26 are 
intermediates in the subsequent β-oxidation pathway [39], and have not been 
previously tested as substrates or inhibitors. Analogues of compounds 23, and 
25 with different side-chains have been previously tested as inhibitors of 
AMACR or MCR [9,30]. Compound 4 was previously reported as the most 
potent AMACR inhibitor [29,32], and is included as an acyl-CoA core ana-
logue. 
 
 
 
2.1. Chemical synthesis of acyl-CoA inhibitors 
 
(2S,3S)-3-Fluoro-2-methyldecanoyl-CoA 21 was synthesised by an 
analogous route to (2R,3R)-3-fluoro-2-methyldecanoyl-CoA 20 [10,28], using 
an Evans’ auxiliary strategy (Scheme 2). Aldol-like reaction of deprotonated 
27 with octanal gave the (2S,3R)-3-hydroxy-2-methyl intermediate 28. From 
here, alcohol 28 was activated and replaced with fluoride with inversion of 
configuration, using DAST to give 3-fluoro-2-methyl derivative 29. The 
reaction is thought to go with 
 
 
 
 
 
 
inversion of stereochemical configuration (by analogy with the work of 
Carnell et al. [28]). Removal of the Evans’ auxiliary from intermediate 29 
provided the carboxylic acid 30 under mild conditions that involved in situ 
generation of lithium hydroperoxide. Intermediate 30 was sub-sequently 
converted to the CoA thioester 21 using the standard syn-thetic method with 
N,N’-carbonyldiimidazole [6,10,11,32,33,40]. This compound was stable in 
solution in the absence of AMACR, showing that the relative geometry of the 
α-proton and fluorine atom was syn-(anti- epimers rapidly eliminate fluoride, 
presumably by an E2 me-chanism [10]). 
 
2-Methylenedecanoyl-CoA 23 was synthesised by an adaptation of the 
method reported by Morgenroth et al. [30] (Scheme 3). Meldrum’s acid 33 
was acylated with octanoic acid 32 using DCC activation; the intermediate 
ketone was reduced to the octyl-Meldrum’s acid 31 with sodium 
triacetoxyborohydride generated in situ. Subsequent reaction of  
31 with Eschenmoser’s salt gave the 2-methylene ester 34. Base-hy-drolysis 
furnished the 2-methylene acid 35, which was coupled with CoA-SH by a 
mixed anhydride approach to give 2-methylenedecanoyl-CoA 23. 
 
2-Methyl-3-oxodecanoyl-CoA 25 was synthesised by the method of Reen 
et al. [41] from 36 (Scheme 4). The ketone in 37 was protected as the cyclic 
acetal 36. Hydrolysis of the ester group in 36 gave the cor-responding acid 
38, which was then coupled with CoA [6,10,11,32,33,40] to give 24. 
Acidolysis of the acetal protection pro-vided 25. 
 
2S,3R-3-Hydroxy-2-methyldecanoyl-CoA 26 was synthesised (Scheme 
5) from the acyl-Evan’s auxiliary 28 (Scheme 2, vide supra) by hydrolysis 
with lithium hydroperoxide to give acid 39, which was converted to the CoA 
ester 26 using the standard procedure [6,10,11,32,33,40]. 
 
 
2.2. Evaluation of inhibitors 
 
The selected AMACR inhibitors were evaluated using the colori-metric 
assay [32]. Incubation of active human AMACR 1A with sub-strate 1 results 
in production of 2,4-dinitrophenolate 2 and unsaturated product 3 (Scheme 
1). Hence, enzyme activity can be determined based on measuring the 
absorbance of 2 at 354 nm over the assay time course. Inhibitory potency was 
assessed using dose–response curves to de-termine IC50 values (Fig. 1). 
 
As expected, ibuprofenoyl-CoA 5 and its derivatives 6–9 were in-hibitors 
of the enzyme, with most having IC50 values of ca. 500 nM (Fig. 1). 
Variation of the structure of the side-chain in these inhibitors appeared to 
make little difference to inhibitory activity (as judged by IC50 values), 
although fenoprofenoyl-CoA 6 appeared to be slightly more potent than the 
other examples and naproxenoyl-CoA 9 appeared to be slightly less so. All 
these compounds are known substrates of AMACR [6] and are predicted to 
behave as competitive inhibitors. Ibuprofenoyl-CoA 5 has been previously 
confirmed to be a competitive inhibitor of AMACR, with Ki = 60 nM [32], 
consistent with observa-tions of other workers on the human and rat enzymes 
[28,37,38]. The mandelic acid derivatives R- and S-2-hydroxy-2-
phenylacetyl-CoA 10 and 11 were also modest inhibitors (Fig. 1), binding 
approximately ten times less strongly than compounds 5–9. Compounds 10 
and 11 are not substrates of AMACR, since enzyme-catalysed α-proton 
exchange does not occur [11]. This result with 10 and 11 also demonstrates 
that in-hibitors can possess a 2-hydroxy- group in addition to the previously 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Structures for AMACR inhibitors, as measured by the colorimetric assay [32]. 
*
Calculated miLogP values are for the acyl-CoA ester (http://www. molinspiration.com/cgi-
bin/properties). 
†
(2R,3R)- and (2S,3S)-3-Fluoro-2-methylhexadecanoyl-CoA were previously shown to be AMACR inhibitors [28]. 
‡
Several side-chain analogues of 23 reported as 
inhibitors [30]. 
‖
Binding of the 2-methylacetoacetyl-CoA enolate to MCR observed by X-ray crystallography [9]. (See above-mentioned references for further information.) 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 2. Synthesis of (2S,3S)-3-fluoro-2-methyldecanoyl-CoA 21. Reagents and conditions: i. Bu2BOTf, Pr
i
2NEt, octanal, CH2Cl2, −78 °C, 76%; ii. DAST, CH2Cl2, −78 °C, 35%; 
iii. LiOH, H2O2, H2O/THF, 0 °C, 92%; iv. CDI, CH2Cl2, rt; v. CoA-SH Li
+
3, 0.1 M NaHCO3 aq./THF (1:1).  
 
 
 
 
 
 
 
 
 
 
 
Scheme 3. Synthesis of 2-methylenedecanoyl-CoA 23. Reagents and conditions: i, DCC, DMAP, CH2Cl2; ii, NaBH4, AcOH, 89% over two steps; iii, Me2N
+
=CH2 I
−
, MeOH, 74%; 
iv, NaOH, EtOH, 80%; v, NEt3, EtOCOCl, THF; vi, aq. KHCO3 (2.5% w/v), CoA-SH Li
+
3, THF. 
 
reported 2-trifluoromethyl- [28] and 2-chloro- [29] groups in place of the 2-
methyl group. A wide range of aromatic inhibitor side-chains can therefore be 
accommodated by the enzyme, consistent with predictions made based on the 
MCR crystal structures [8] and biochemical data [6,11]. 
 
Acyl-CoA esters 12–17, possessing alkyl side-chains, were also as-sessed 
as inhibitors (Fig. 1). The potency of inhibition for acyl-CoA esters with side-
chains of four carbons or fewer (15–17) is very weak, with low levels of 
inhibition (15–30%) observed even at very high in-hibitor concentrations 
(100 µM). Inhibition increased as alkyl chain-length increased. This 
behaviour is consistent with that of straight-chain acyl-CoA esters acting as 
substrates [36], where increased levels of α-proton exchange are observed 
with increasing chain length. Our results showing inhibition of AMACR by 
straight-chain acyl-CoA esters contrasts with the early observations of 
Schmitz et al., who reported that these compounds were not inhibitors of the 
native human and rat enzymes [37,38]. 
 
Inclusion of a 2-methyl group on the inhibitor increased potency by about 
3-fold (compounds 18 and 19 compared to 12), again consistent with the 
finding that 2-methylacyl-CoA esters are much more efficient substrates than 
their straight-chain equivalents [36]. R-2-Methyldeca-noyl-CoA 18 appeared 
to be a slightly more potent inhibitor than S-2- 
 
 
methyldecanoyl-CoA 19, and this probably reflects the physiological role of 
AMACR in the conversion of R-2-methylacyl-CoAs to their S-2-methylacyl-
CoA epimers [1,2].  
2-Methyldecanoyl-CoA derivatives with more acidic α-protons are better 
inhibitors than their parent compounds (Fig. 1). R,R-3-Fluoro-2-
methyldecanoyl-CoA 20 was about 5-fold more potent than was R-2-
methyldecanoyl-CoA 18. A similar trend was observed with S,S-3-fluoro-2-
methyldecanoyl-CoA 21 and S-2-methyldecanoyl-CoA 19, al-though both of 
these compounds were slightly less potent than their R-epimers. The product 
of the reaction, E-2-methyldec-2-enoyl-CoA 22, is also a potent inhibitor. It 
is therefore difficult to determine if the ob-served IC50 values for 20 or 21 
reflect the conversion of these substrates [10], product inhibition by 22 or 
both. These observations contrast with early studies [37,38], which suggest 
that 22 was not an inhibitor of AMACR. 
 
2-Methyl-3-oxodecanoyl-CoA 25 was also a good inhibitor of AMACR. 
The α-proton of this compound is relatively acidic and 25 undergoes rapid 
non-enzymatic α-proton exchange with solvent via an enolate intermediate. It 
was therefore not possible to analyse the in-fluence of 2-methyl group 
stereochemical configuration. The precursor 24 was a much poorer inhibitor 
than 25, presumably due to reduced acidity of the α-proton. It is also possible 
that the additional steric bulk 
 
 
 
 
 
 
 
 
 
 
 
Scheme 4. Synthesis of 2-methyl-3-oxodecanoyl-CoA 25. Reagents and conditions: i, ethane-1,2-diol, TMSCl, CH2Cl2, 82%; ii, aq. NaOH/MeOH, 40%; iii, CDI, CH2Cl2; v, CoA-SH 
Li
+
3, 0.1 M NaHCO3 aq./THF (1:1); iv, aq. HCl, acetone. 
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Fig. 2. Incubation of 2S,3R-3-hydroxy-2-methyldecanoyl-CoA 26 with AMACR in 
buffer and 
2
H2O. A. Heat-inactivated enzyme; B. live enzyme. Red circles highlight 
doublet for substrate 2-methyl group, showing no exchange of the α-proton had occurred 
(conversion to a single peak occurs on exchange to α-
2
H upon ‘racemisation’ [7,11]). 
Green circles denote expected position of 2-methyl singlet for the expected unsaturated 
product 22, showing that no elimination reaction has occurred. 
 
 
at carbon-3 contributes to the lower potency of 24 compared to 25, as the 5-
membered ring of 24 will be twisted out of plane relative to the aliphatic side-
chain. However, AMACR is known to be able to accept substrates with 
diverse side-chain structures [6,28,36–38] and it is notable that ibuprofenoyl-
CoA 5 and derivatives 6–9 (which have aromatic rings at the equivalent 
position) are potent inhibitors (Fig. 1).  
2S,3R-3-Hydroxy-2-methyldecanoyl-CoA 26 is also a relatively po-tent 
inhibitor. Incubation of 26 with active AMACR did not result in an 
elimination reaction, as judged by the lack of a peak at δ 1.75 ppm [10] from 
the 2-methyl group of the anticipated product 22 (Fig. 2), prob-ably because 
hydroxide is a relatively poor leaving group (water pKa = ∼14.0–15.7), 
compared to fluoride (HF pKa = 3.2) [42]. Simi-larly, 
1H NMR analysis of the 
reaction products showed that 26 did not undergo α-proton exchange, and 
hence 26 is not a substrate of AMACR. It is notable that 22, 24 and 26 are 
intermediates in the branched-chain acyl-CoA β-oxidation pathway. One may 
speculate that these com-pounds could provide some regulation of AMACR 
by negative feedback control, and hence control entry of R-2-methylacyl-CoA 
esters into the β-oxidation pathway. Whether or not this is physiologically 
significant will depend on rates of flux through the β-oxidation pathway and 
whether intermediates 22, 24 and 26 are sequestered away from AMACR. 
 
 
Acyl-CoAs which mimic the planar enolate intermediate are good 
inhibitors of AMACR (Fig. 1). E-2-Methyldec-2-enoyl-CoA 22 and 2-
methylenedecanoyl-CoA 23 bind strongly due to having a planar sp2-
hybridized α-carbon. This result is consistent with a previous study in which 
2-methyleneacyl-CoAs were shown to be good competitive 
 
 
Scheme 5. Synthesis of (2S,3R)-3-hydroxy-2-
methyldecanoyl-CoA 26. Reagents and condi-tions: i. 
NaOH, H2O2, rt, quant.; ii. CDI, CH2Cl2, rt; iii. CoA-
SH Li
+
3, 0.1 M NaHCO3 aq./THF (1:1).  
 
 
 
inhibitors [2,30]. The enolate analogue N-dodecyl-N-methylcarbamoyl-CoA 
4 is the best rationally designed inhibitor (IC50 = 0.4 nM) reported to date 
[29,32]. Inhibition by 4 is ca. 2000× more potent than by 18 and 19 (Fig. 1). 
This high potency of 4 appears to largely result from the mimicking of the 
enolate intermediate by the carbamoyl moiety. It is also notable that the 
determined IC50 value for 4 in this study (0.4 nM) is significantly lower than 
that previously determined by Carnell et al. (98 nM), when assayed against 
HEK-derived human AMACR using ibuprofenoyl-CoA 5 as substrate [29]. It 
appears that the colorimetric assay consistently determines higher levels of 
compound potency than other assays (e.g. Ki = 60 nM [32] vs. 56 µM [28,38] 
for an ibuprofe-noyl-CoA epimeric mixture) The reasons for this discrepancy 
is not entirely clear, but higher apparent potency may be a consequence of 
using a substrate undergoing an irreversible reaction to measure ac-tivity (and 
hence avoiding the error introduced by the presence of the reverse reaction). 
Alternatively, this may be related to the extent of substrate or inhibitor 
micelle formation under the different assay con-ditions. 
 
 
The determined IC50 value of 4 (0.4 nM) is around half the calcu-lated 
‘active’ enzyme concentration in the assay [32] (based on com-parison of 
kcat/Km values for the E. coli and HEK cell derived enzymes [29]). Hence 4 
could be behaving as a tight-binding inhibitor. Com-pound 4 behaves as a 
rapidly reversible competitive inhibitor of AMACR, with a Hill coefficient of 
∼0.7 [32]. These observations are consistent with the zone A inhibitor 
behaviour described by Straus and Goldstein [43,44], i.e. the enzyme active 
site concentration is < 0.1 × the apparent Ki value (0.65 nM [32]). This 
rapidly reversible inhibition is significantly different behaviour to that 
observed for similar com-pounds (gem- carbamoyl inhibitors and N-decyl-
carbamoyl-CoA) with the highly homologous bacterial enzyme MCR, where 
time-dependent inactivation was observed [35]. The reasons for this difference 
in be-haviour are not entirely obvious. 
 
 
2.3. Influence of the side-chain lipophilicity on inhibitor potency 
 
AMACR is able to catalyse the ‘racemisation’ of substrates with 
structurally diverse side-chains [1,2]. The accommodation of these di-verse 
structures is thought to be a result of non-specific binding of the side-chain by 
hydrophobic interactions to a methionine-rich surface [8]. Consistent with 
this, the MCR gem- [31] and gem- carbamate [35] inhibitors show increased 
potency for compounds with more hydro-phobic alkyl side-chains. 
Consequently, we were interested to in-vestigate whether inhibitor potency 
was related to the lipophilicity of the inhibitor side-chain. A plot of 
determined IC50 values vs. calculated LogP values for the acyl-CoA inhibitor 
(Fig. 3) showed that high LogP values tend to produce low IC50 values. 
Systematic trends were ob-served within those compounds containing 
aromatic side-chains (5–11), with potency positively correlating with 
lipophilicity. It is also notable that 10 and 11, possessing a single phenyl 
group side-chain are significantly less potent than compounds containing 
more lipophilic side-chains. This consistent behaviour tends to suggest that 
side-chain lipophilicity is driving potency, with the 2-hydroxy group of 10 
and 11 making a smaller contribution. Systematic trends were also observed 
for inhibitors possessing alkyl side-chains (12–17), showing that lipo-
philicity is also an important determinant of potency for this series. 
 
The enolate analogue 4 has a potency increased by ∼875-fold compared 
to that predicted based on LogP values (measured IC50 = ∼0.4 nM vs. ∼350 
nM predicted for miLogP = 2.61) (Supplementary Information, Fig. S1), 
showing the effectiveness of the 
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Fig. 3. Correlation of inhibitor potency with lipophilicity (miLogP value; 
http://www.molinspiration.com/cgi-bin/properties). Compound numbers refer to 
structures shown in Fig. 1. Compounds with green numbers are those with aromatic side-
chains (5–11); Compounds with blue numbers are straight-chain acyl-CoA esters and 
isobutanoyl-CoA (12–17); Compounds with purple num-bers are 2-methyldecanoyl-
CoA and 3-fluoro-2-methyldecanoyl-CoAs (18–21); Compounds with orange numbers 
are intermediates in the β-oxidation pathway which occurs subsequent to AMACR 
activity (22, 25 and 26); Compounds with red numbers are inhibitors or analogues of 
known inhibitors (4 and 23); Compound 24 is a synthetic intermediate to 25. 
 
 
carbamate moiety in promoting inhibition. Acyl-CoA esters do not comply 
with Lipinski guidelines and hence AMACR inhibitors are de-livered as their 
acid pro-drugs [28,30,32,34] which are converted to the acyl-CoA in vivo. 
Although 4 has very high potency, delivery as the pro-drug will be 
challenging because carbamates readily decarboxylate to the corresponding 
amine. 
 
3. Conclusions 
 
This is the first systematic SAR study of rationally designed AMACR 
inhibitors. The study illustrates that extremely diverse side-chain structures 
which can be accommodated. A minimal level of side-chain lipophilicity is 
required for efficient binding. For compounds with aromatic side-chains, a 
single aromatic ring results in modest inhibition whilst more than one 
aromatic ring or an aromatic ring with alkyl substituents results in much more 
potent inhibition. Similarly, a minimum of a 6-carbon alkyl chain appears to 
be required for reason-ably efficient inhibitor binding, with increased potency 
resulting from addition of further –CH2– groups. Our results allow 
investigation of the contribution to potency made by the individual structural 
elements of these inhibitors. 
 
AMACR has attracted much attention as both a novel drug target and 
cancer marker since its involvement in prostate cancer was re-ported [14,19]. 
However, exploitation of this discovery has been ex-tremely limited, largely 
due to the absence of a suitable assay with which to test inhibitor potency 
[33]. This study shows that our novel colorimetric assay [32] allows quick 
and accurate measurement of drug potency and detailed kinetic 
characterisation of inhibitors. The sys-tematic investigation of novel inhibitor 
SAR and therapeutic develop-ment is now possible. 
 
 
4. Materials and methods 
 
4.1. Sources of materials 
 
Chemicals were purchased from the Sigma-Aldrich Chemical Co. or 
Fisher Scientific Ltd., unless otherwise stated, and were used without further 
purification. Reduced coenzyme A, tri-lithium salt, was 
 
 
purchased from Calbiochem. Acyl-CoA esters 4 [33], 5–9 [6], 10 and 11 
[11] were synthesised as previously described. Acyl-CoA esters 12–17 were 
purchased from Larodan Lipids. Substrates 18–20 and product 22 were 
synthesised as described [7,10]. Human recombinant AMACR 1A was 
expressed and purified and substrate 1 synthesised as previously described 
[32]. 
 
4.2. General experimental procedures 
 
Thin layer chromatography was performed on Merck silica alumi-nium 
plates 60 (F254) and UV light, potassium permanganate or phosphomolybdic 
acid were used for visualisation. Column chromato-graphy was performed 
using Fisher silica gel (particle size 35–70 µm). Purifications of acyl-CoA 
esters were performed by solid phase extrac-tion using Oasis HLB 6cc (200 
mg) extraction cartridges. Phosphate buffer was prepared from monobasic 
sodium phosphate and NaOH at the required proportions. Citric acid buffer 
was prepared from citric acid and NaOH at the required proportion for 0.8 M 
pH 4.0 buffer. The pH of aqueous solutions was measured using a Corning 
240 pH meter and Corning general purpose combination electrode. The pH 
meter was calibrated using Fisher Chemicals standard buffer solutions (pH 4.0 
– phthalate, 7.0 – phosphate, and 10.0 – borate) at either pH 7.0 and 10.0 or 
7.0 and 4.0. Calibration and measurements were carried out at ambient room 
temperature. IR spectra were recorded on Perkin-Elmer RXI FTIR 
spectrometer instrument. NMR spectra were recorded on Bruker Avance III 
400.04 MHz or 500.13 MHz spectrometers in D2O, (CD3)2SO or CDCl3 and 
the solvent was used as an internal standard. Shifts are given in ppm and J 
values reported to ± 0.1 Hz. Multiplicities of NMR signals are described as 
follows: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet. Stock 
concentrations of acyl-CoA esters for assays were determined using 1H NMR. 
Mass spectra were recorded by ESI TOF. High resolution mass spectra were 
recorded in ES mode. Melting points were determined using a Gallenkamp 
melting point apparatus and are uncorrected. Syntheses were carried out at 
ambient temperature, unless otherwise specified. Solutions in organic solvents 
were dried over anhydrous MgSO4 and the solvents were evaporated under 
reduced pressure. Aqueous solutions for biological experiments were 
prepared in Nanopure water of 18.2 MΩ.cm−1 quality and were pH-adjusted 
with aq. HCl or NaOH. 
 
 
 
4.3. (4S)-4-Benzyl-3-[(2S,3R)-3-hydroxy-2-methyldecanoyl]-1,3-
oxazolidin-2-one (28) 
 
(S)-(+)-4-Benzyl-3-propanoyl-2-oxazolidinone 27 (3.0 g, 
12.9 mmol) in CH2Cl2 (30.0 mL) was cooled to -78 °C. Dibutylboron triflate 
(1.0 M in CH2Cl2, 13.0 mL, 12.9 mmol) and Pr
i
2NEt (2.3 mL, 12.9 mmol) 
were added and the mixture was stirred for 30 min before octanal (1.4 mL, 9.2 
mmol) in CH2Cl2 (9.0 mL) was added dropwise. The mixture was stirred at -
78 °C for further 30 min and then at room temperature for 2 h. aq. Sodium 
phosphate buffer at pH 7.0 (100 mM, 100 mL) was added slowly to the 
reaction mixture. The organic layer was washed [aq. HCl (1.0 M), aq. 
NaHCO3 (saturated), brine] and dried. Column chromatography (Petroleum 
ether/EtOAc 10:1 → 6:1) gave 28 (2.53 g, 76%) as a colourless oil. [α]D
21 
+51.4 (c 0.74 in CHCl3); IR νmax 3517 (OH), 1780 (C]O), 1692 (C]O) cm
−1; 
1H NMR (500.13 MHz; CDCl3) δH 7.26–7.07 (5H, m, Ar-H), 4.65–4.55 (1 
H, m, 4-H), 4.16–4.05 (2 H, m, 5-H), 3.89–3.80 (1 H, m, 3′-H), 3.68 (1 H, qd 
J = 7.0, 3.0 Hz, 2′-H), 3.14 (1 H, dd, J = 13.0, 3.0 Hz, CHHAr), 2.92 (1 H, s, 
OH), 2.70 (1 H, dd, J = 13.0, 9.0 Hz, CHHAr), 1.50–1.10 (15H, m, 6 × CH2 
and CH3CH), 0.79 (3 H, t, J = 6.5 Hz, 10′-H3); 
13C NMR (125.77 MHz, 
CDCl3) δC177.23 (1′-C), 152.87 (2-C), 134.92 (Ar-C), 129.24 (Ar-C), 128.73 
(Ar-C), 127.18 (Ar-C), 71.35 (3′-C), 65.96 (5-C), 54.91 (4-C), 42.02 (2′-C), 
37.53 (CHHAr), 33.77 (CH2), 31.62 (CH2),  
29.35 (CH2), 29.05 (CH2), 25.84 (CH2), 22.45 (CH2), 13.90 (CH3CH), 
10.31 (10′-C); ESI-MS m/z 384.2134 [M+Na]+ (C21H31NNaO4 requires 
384.2151). 
 
 
  
4.4. (4S)-4-Benzyl-3-[(2R,3S)-3-fluoro-2-methyldecanoyl]-1,3-
oxazolidin-2-one (29) 
 
(Diethylamino)sulfur  trifluoride  (0.5 mL,  3.9 mmol)  in  CH2Cl2 
(10.0 mL) was added dropwise to 28 (1.4 g, 3.9 mmol) in CH2Cl2  
(20.0 mL) at −78 °C and the mixture was stirred for 2 h at this tem-perature. It 
was stirred for a further 2 h at room temperature, before being quenched with 
water (50 mL). The organic layer was washed (saturated aq. NaHCO3, brine). 
Column chromatography (petroleum ether/EtOAc 30:1 gave 29 (490 mg, 
35%) as a colourless oil. [α]D
21 +49.2 (c 0.63 in CHCl3); IR νmax 1782 
(C]O), 1700 (C]O) cm−1; 1H NMR (500.13 MHz; CDCl3) δH 7.27–7.06 (5H, 
m, Ar-H), 4.76–4.57 (2H, m, 4-H and 3′-H), 4.15–3.96 (3 H, m, 5-H and 2′-
H), 3.17 (1 H, dd, J = 13.5, 3.5 Hz, CHHAr), 2.72 (1 H, dd, J = 13.5, 9.5 Hz, 
CHHAr), 1.70–1.14 (12H, m, 6 × CH2), 1.10 (3 H, d, J = 7.0 Hz, CH3CH), 
0.80 (3 H, t, J = 6.5 Hz, 10′-H3); 
13C NMR (125.77 MHz, CDCl3) δC 174.37 
(d, J = 2.8 Hz, 1′-C), 153.12 (2-C), 135.25 (Ar-C), 129.47 (Ar-C), 128.93 (Ar-
C), 127.37 (Ar-C), 94.89 (d, J = 169.8 Hz, 3′-C), 66.19 (5-C), 55.38 (4-C), 
42.03 (d, J = 20.9 Hz, 2′-C), 37.85 (CHHAr), 32.04 (d, 
 
J = 20.9 Hz, 4′-CH2), 31.79 (CH2), 29.37 (CH2), 29.16 (CH2), 24.57 (d, 
J = 2.8 Hz, 5′-CH2),  22.64  (CH2),  14.10  (10′-C)  and  13.62  (d, 
J = 8.5 Hz,  2′-CH3);  δF  (470 MHz,  CDCl3)  −179.67;  ESI-MS  m/z 
386.2126 [M+Na]+ (C21H30FNNaO3 requires 386.2107). 
 
4.5. (2R,3S)-3-Fluoro-2-methyldecanoic acid (30) 
 
aq. H2O2 [30% (w/w), 0.7 mL] and LiOH (62 mg, 2.6 mmol) were added 
to 29 (472 mg, 1.3 mmol) in THF (14 mL) at 0 °C. The mixture was stirred at 
ambient temperature for 20 h before being quenched with sat. aq. sodium 
sulfite (14 mL). The THF was evaporated and the mix-ture was acidified with 
aq. HCl (1.0 M) to pH 1.0 and extracted with CH2Cl2 (100 mL). The organic 
phase was washed with water (75 mL) and brine (75 mL). The combined 
organic layers were dried and the solvent was evaporated. Column 
chromatography (petroleum ether/  
EtOAc 5:1) gave 30 (245 mg, 92%) as a white solid. mp 64–65 °C; [α]D
21 
−7.8 (c 0.51 in CHCl3); IR νmax 2925 (OH), 1693 (C]O) cm
−1; 1H NMR 
(400.04 MHz; CDCl3) δH 10.89 (1H, br s, OH), 4.58–4.50 (1H,  
m, 3-H), 2.58–2.52 (1H, m, 2-H), 1.75–1.23 (12H, m, 6 × CH2), 1.20 (3H, d, 
J = 7.2 Hz, CH3CH), 0.88 (3H, t, J = 6.8 Hz, 10-H3); 
13C NMR  
(100.60 MHz, CDCl3) δC 180.02 (d, J = 5.6 Hz, C]O), 94.28 (d, J = 172.2 Hz, 
3-C), 44.37 (d, J = 22.0 Hz, 2-C), 31.74 (d, J = 21.1 Hz,  
4-CH2), 31.74 (CH2), 29.30 (CH2), 29.12 (CH2), 24.82 (d, J = 3.0 Hz, 5-
CH2), 22.61 (CH2), 14.05 (10-C) and 12.56 (d, J = 6.6 Hz, 2-CH3); 
19F  
NMR (470 MHz, CDCl3) δF −181.94; ESI-MS m/z 203.1449 [M−H]
− 
(C11H20FO2 requires 203.1447). 
 
4.6. (2S,3S)-3-Fluoro-2-methyldecanoyl-CoA (21) 
 
N,N’-Carbonyldiimidazole (48 mg, 0.29 mmol) was added to (2R,3S)-3-
fluoro-2-methyldecanoic acid 30 (30.0 mg, 0.15 mmol) in anhydrous CH2Cl2 
(2 mL) and the mixture was stirred at ambient temperature for 1 h. CH2Cl2 (3 
mL) was added to the mixture, which was washed with water (5 × 2 mL) and 
brine (2 mL) and dried. The solvent was evaporated to obtain the crude acyl-
imidazole inter-mediate. Aq. NaHCO3 (1.0 mL, 0.10 M) and tri-lithium CoA-
SH (17.0 mg, 0.02 mmol) was added to the crude intermediate in THF (1.0 
mL) and the mixture was stirred at ambient temperature for 18 h. The THF 
was evaporated and the residue was acidified to ca. pH 3 by addition of aq. 
HCl (1.0 M). The mixture was diluted with water (2.0 mL) and washed with 
EtOAc (3 × 3 mL). The crude aqueous so-lution was freeze-dried and purified 
with solid-phase extraction to give 
 
21 (13.6 mg) as a white solid. 1H NMR (500 MHz, D2O) δH 8.63 (1H, s, 
adenosine CH), 8.38 (1H, s, adenosine CH), 6.16 (1H, d, J = 6.0 Hz, 
adenosine CH), 4.30–4.10 (2H, m, adenosine CH2), 3.97 (1H, s, ade-nosine 
CH), 3.85–3.72 (1H, m, CoA(OCHH)), 3.58–3.47 (1H, m, CoA(OCHH)), 
3.39 (2H, t, J = 6.5 Hz, CoA(CH2)), 3.29 (2H, t, 
 
 
J = 6.0 Hz, CoA(CH2)), 3.08–2.90 (3H, m, CoA(SCH2) and CHCH3), 2.36 
(2H, t, J = 6.5 Hz, CoA(CH2)), 1.68–1.44 (2H, m, CHH and CHH),  
1.39–1.12 (10H, m, 5 × CH2), 1.07 (3H, d, J = 7.0 Hz, CHCH3), 0.87 (3H, s, 
CoA(CH3)), 0.81–0.70 (6H, m, CH2CH3 and CoA(CH3)); 
19F NMR (470 
MHz) δF −181.11; ESI-MS m/z 475.6220 [M−2H]
2− (C32H53FN7O17P3S 
requires 475.6208). 
 
4.7. 2,2-Dimethyl-5-octyl-1,3-dioxane-4,6-dione (31) 
 
4-Dimethylaminopyridine (1.296 g, 10.6 mmol), N,N’-dicyclohex-
ylcarbodiimide (1.0 M in CH2Cl2, 11.1 mL, 11.1 mmol) and octanoic acid 32 
(1.6 mL, 10 mmol, 1.0 eq.) were added to Meldrum’s acid 33 (1.455 g, 10.1 
mmol) in dry CH2Cl2 (100 mL). The mixture was stirred at ambient 
temperature for 40 h. The precipitate was removed by fil-tration and the 
filtrate was washed with aq. KHSO4 (1.0 M, twice), water and brine, then 
dried. AcOH (6.0 mL) was added to the filtrate. To this solution, NaBH4 (802 
mg, 21.2 mmol) was added in portions during 1 h and the mixture was stirred 
for an additional 20 h. The evaporation residue was dissolved in Et2O (100 
mL) and washed with water (twice) and brine (100 mL). Drying and 
evaporation gave 31 (2.30 g, 89%) as a white solid: mp. 64–65 °C (lit. [45] 
mp. 65–67 °C); 1H NMR (400.04 MHz, CDCl3): δH 3.49 (1H, t, J = 4.9 Hz, 
dioxane 5-H), 2.14–2.04 (m, 2H, octyl 1-H2), 1.77 (3H, s, 2-CH3), 1.75 (3H, 
s, 2-CH3), 
1.48–1.38 (2H, m, octyl 3-H2), 1.37–1.19 (10H, m, octyl 4,5,6,7-H8), 
0.86 (3H, t, J = 7.0 Hz, octyl 8-H3); 
13C NMR (125.77 MHz, CDCl3): δC 
165.6, 104.7, 46.1, 31.8, 29.5, 29.2, 29.1, 28.4, 26.9, 26.6, 26.5, 22.6, 14.1; IR 
(KBr disc) nmax 1752 (C]O) cm
−1; ESI-MS m/z 279.1577 [M +Na]+ 
C14H24NaO4 requires 279.1572; 257.1732 [M+H]
+ (C14H25O4 requires 
257.1753). 
 
4.8. Methyl 2-methylenedecanoate (34) 
 
Compound 31 (2.10 g, 8.19 mmol) was dissolved in anhydrous MeOH 
(26 mL). Eschenmoser's salt (3.79 g, 20.5 mmol, 2.5 eq.) was added and the 
mixture was heated at reflux for 40 h. The solvent was evaporated. The 
residue, in Et2O (100 mL), was washed with aq. KHSO4 (1.0 M), water and 
brine and was dried. Evaporation and column chromatography (petroleum 
ether/EtOAc 10:1) gave 34 (1.10 g, 74%) as a colourless oil (lit.[46] oil): IR 
(neat) nmax 1725 (C]O) cm
−1; 1H NMR (400.04 MHz, CDCl3): δH 6.12–6.10 
(1H, m, ]CHH), 5.52–5.49 (1H, m, ]CHH), 3.73 (3H, s, OCH3), 2.31–2.23 
(2H, m, 3-H2), 1.49–1.37 (2H, m, 4-H2), 1.34–1.19 (10H, m, 5,6,7,8,9-H10), 
0.86 (3H, t, J = 7.1 Hz, 10-H3); 
13C NMR (125.77 MHz, CDCl3): δC 167.8, 
140.8, 124.4, 51.7 (two carbons), 31.8, 29.3, 29.2, 29.2, 28.3, 22.6, 14.0. 
 
 
4.9. 2-Methylenedecanoic acid (35) 
 
Methyl ester 34 (870 mg, 4.39 mmol) was stirred at 50 °C for 2 h with aq. 
NaOH (1.0 M, 15 mL, 15 mmol) in EtOH (57 mL), then cooled to ambient 
temperature and acidified to pH ca. 3. The volatile solvents were evaporated. 
The residue, in Et2O (50 mL), was washed with water (twice) and brine and 
was dried. Evaporation and column chromato-graphy (petroleum ether/EtOAc 
3:1) gave 35 (650 mg, 80%) as a col-ourless oil (lit. [47] oil): IR (neat) nmax 
1696 (C]O) cm−1; 1H NMR (400.04 MHz, CDCl3): δH 12.05 (1H, br s), 
6.34–6.23 (1H, m, ]CHH), 5.70–5.59 (1H, m, =CHH), 2.32–2.25 (2H, m, 3-
H2), 1.54–1.40 (2H, m, 4-H2), 1.36–1.19 (10H, m, 5,6,7,8,9-H10), 0.87 (3H, 
t, J = 7.0 Hz, 10-H3); 
13C NMR (125.77 MHz, CDCl3): δC 173.0, 140.2, 
126.9, 31.8, 31.4, 29.3, 29.2, 29.2, 28.3, 22.6, 14.1; ESI-MS m/z 207.1349 
[M+Na]+ C11H20NaO2 requires 207.1361); 183.1396 [M−H]
− (C11H19O2 
re-quires 183.1385). 
 
4.10. 2-Methylenedecanoyl-CoA (23) 
 
Ethyl chloroformate (17 µL, 19 mg, 0.18 mmol) was added to 35 
(33 mg, 0.18 mmol) and NEt3 (25 µL, 18 mg, 0.18 mmol) in anhydrous 
 
 
  
 
THF (2.0 mL) and the mixture was stirred at ambient temperature for 1 h. 
CoA-SH tri-lithium salt [(28 mg, 0.04 mmol) in aq. KHCO3 (2.5%), 2.0 mL] 
was added and the mixture was stirred at ambient temperature for 16 h. The 
mixture was acidified to pH ca. 3 with aq. HCl (1.0 M) and the THF was 
evaporated. The solution was washed with EtOAc (5 × 3 mL) and the crude 
product was purified by SPE to give 23 (7.0 mg) as a colourless solid: 1H 
NMR (500.13 MHz, D2O): δH 8.47 (1H, s), 8.16 (1H, s), 6.07 (1H, d, J = 7.0 
Hz), 5.96 (1H, s), 5.55 (1H, s), 4.19–4.11 (1H, m), 3.75 (1H, dd, J = 9.8, 5.1 
Hz), 3.46 (1H, dd, J = 9.8, 4.8 Hz), 3.36 (2H, t, J = 6.5 Hz), 3.31–3.25 (2H, 
m), 2.95 (2H, t, J = 6.2 Hz), 2.33 (2H, t, J = 6.6 Hz), 2.16 (2H, t, J = 7.3 Hz), 
1.30–1.22 (2H, m), 1.18–1.06 (10H, m), 0.79 (3H, s), 0.75 (3H, t, J = 6.8 Hz), 
0.65 (3H, s); ESI-MS m/z 465.6152 [M−2H]2− (C32H52N7O17P3S requires 
465.6177). 
 
 
4.11. Methyl 2-(2-heptyl-1,3-dioxolan-2-yl)propanoate (36) 
 
Ethane-1,2-diol (5.27 g, 84.8 mmol) was added to 37 (606 mg, 2.83 
mmol) in dry CH2Cl2 (26 mL). Me3SiCl (1.84 g, 2.15 mL, 17.0 mmol) was 
added and the mixture was stirred at ambient tem-perature for 3 d. Further 
ethane-1,2-diol (5.27 g) and Me3SiCl (1.84 g) were added and the mixture 
was stirred for a further 3 d. Water (25 mL) was added and the mixture was 
extracted with CH2Cl2 (3 × 20 mL). The combined organic layers were 
washed with water (5 × 70 mL) and brine (70 mL) and were dried. 
Evaporation and column chromato-graphy (petroleum ether/EtOAc 10:1) 
gave 36 (600 mg, 82%) as a colourless oil: IR (neat) nmax 1740 (C]O) cm
−1; 
1H NMR (400.04 MHz, CDCl3) δH 4.04–3.90 (4H, m, OCH2CH2O), 3.67 
(3H, s, OCH3), 2.83 (1H, q, J = 7.2 Hz, CHCH3), 1.81–1.62 (2H, m, heptyl 1-
H2), 1.42–1.20 (10H, m, heptyl 2,3,4,5,6-H10), 1.18 (3H, d, J = 7.2 Hz, 
propanoate 3-H3), 0.86 (3H, t, J = 7.1 Hz, heptyl 7-H3); 
13C NMR (125.77 
MHz, CDCl3): δC 173.9, 111.3, 65.5, 65.4, 51.7, 46.7, 35.0, 31.7, 29.7, 29.2, 
22.8, 22.6, 14.0, 12.5; ESI-MS m/z 281.1761 [M+Na]+ (C14H26NaO4 
requires 281.1729), 259.1883 [M+H]+ (C14H27O4 requires 259.1909). 
 
4.12. 2-(2-Heptyl-1,3-dioxolan-2-yl)propanoic acid (38) 
 
Aq. NaOH (1.0 M, 6.7 mL, 6.7 mmol) was stirred with 36 (345 mg, 1.34 
mmol) in MeOH (30 mL) at ambient temperature for 2 h, then at 65 °C for 2 
h. The mixture was cooled to ambient temperature and citric acid buffer (0.8 
M, pH 4.0, 15 mL) was added. The mixture was ex-tracted with CH2Cl2 (3 × 
30 mL). The combined organic layers were washed with water and brine and 
dried. Evaporation and column chromatography (petroleum ether/EtOAc 2:1) 
gave 38 (130 mg, 40%) as a colourless oil. IR (neat) nmax 1709 (C]O) cm
−1; 
1H NMR (400.04 MHz, CDCl3): δH 10.78 (1H, br s, OH), 4.10–3.94 (4H, m, 
OCH2CH2O), 2.83 (1H, q, J = 7.2 Hz, CHCH3), 1.80–1.67 (2H, m heptyl 1-
H2), 1.43–1.20 (10H, m, heptyl 2,3,4,5,6-H10), 1.23 (3H, d, J = 7.2 Hz, 
CHCH3), 0.87 (3H, t, J = 7.1 Hz, heptyl 7-H3); 
13C NMR (125.77 MHz, 
CDCl3): δC 176.9, 111.4, 65.4, 65.4, 46.6, 34.7, 31.7, 29.6, 29.2, 22.8, 22.6, 
14.0, 12.2; ESI-MS m/z 267.1549 [M+Na]+ (C13H24NaO4 requires 
267.1572), 245.1729 [M+H]+ (C13H25O4 re-quires 245.1753). 
 
 
4.13. 2-(2-Heptyl-1,3-dioxolan-2-yl)propanoyl-CoA (24) 
 
Using the same method as for 21, 24 was prepared from 38 (31 mg, 0.13 
mmol, 1.0 eq.) by sequential treatment with N,N’-carbonyldiimi-dazole (41 
mg, 0.25 mmol, 2.0 eq.) and CoA-SH tri-lithium salt (29 mg, 0.04 mmol, 0.3 
eq.) to give 24 (10 mg) as a colourless solid: 1H NMR 
(500.13 MHz, D2O) δH 8.57 (1H, s), 8.30 (1H, s), 6.13 (1H, d, 
J = 6.1 Hz), 4.21–4.14 (1H, m), 3.99–3.88 (4H, m), 3.78 (1H, dd, 
J = 9.6,  4.5 Hz),  3.50 (1H, dd, J = 9.7, 4.5 Hz), 3.39  (2H,  t, 
J = 6.6 Hz), 3.32–3.22 (2H, m), 3.12 (1H, 2 × q, J = 7.0 Hz; both 
epimers), 2.93 (2H, t, J = 6.2 Hz), 2.36 (2H, t, J = 6.6 Hz), 1.66–1.53 (2H, m), 
1.26–1.11 (8H, m), 1.08 (3H, d, J = 7.0 Hz, CHCH3), 0.85 (3H, 
 
 
s), 0.76 (3H, t, J = 7.1 Hz, CH2CH3), 0.72 (3H, s); ESI-MS m/z 506.6219 
[M+Na]2+ (C34H55N7NaO19P3S requires 506.6192), 495.6301 [M +H]
2+ 
(C34H56N7O19P3S requires 495.6282). 
 
4.14. 2R,S-2-Methyl-3-oxodecanoyl-CoA (25) 
 
Compound 24 (7 mg, 7.1 µmol) was dissolved in water (0.8 mL) and 
acetone (1.0 mL). Aq. HCl (1.0 M, 0.2 mL) was added and the reaction 
mixture was stirred overnight. The acetone was evaporated and the residue 
freeze-dried to give 25 (6 mg) as a colourless solid: 1H NMR (500.13 MHz, 
D2O): δH 8.49 (1H, s), 8.33 (1H, s), 6.10 (1H, d, J = 5.8 Hz), 4.20–4.10 (2H, 
m), 3.99 (1H, q, J = 7.0 Hz), 3.76 (1H, dd, J = 9.7, 5.0 Hz), 3.38–3.28 (2H, 
m), 3.22 (2H, t, J = 6.3 Hz), 2.97–2.88 (2H, m), 2.57–2.44 (2H, m), 2.30 (2H, 
t, J = 6.6 Hz), 1.41–1.32 (2H, m), 1.16 (3H, d, J = 7.0 Hz), 1.12–1.04 (8H, 
m), 0.80 (3H, s), 0.69 (3H, s), 0.68 (3H, t, J = 7.0 Hz); ESI-MS m/z 473.6174 
[M−2H]2− (C32H52N7O18P3S requires 473.6151). 
 
 
 
4.15. 2S,3R-3-Hydroxy-2-methyldecanoyl-CoA (26) 
 
2S,3R-3-Hydroxy-2-methyldecanoic acid 39 was synthesised [48] from 
the Evan’s auxiliary-protected acid 28 by hydrolysis with LiOH and H2O2. 
Following the procedure used for 21, 2S,3R-3-hydroxy-2-methyldecanoyl-
CoA 26 was prepared from 2S,3R-3-hydroxy-2-me-thyldecanoic acid 39 (40 
mg, 0.20 mmol, 1.0 eq.), CDI (64 mg, 0.40 mmol, 2.0 eq.) and CoA-SH tri-
lithium salt (78 mg, 0.10 mmol,  
0.5 eq.) to give 26 (12 mg) as a colourless solid: 1H NMR (500.13 MHz, 
D2O) δH 8.48 (1H, s), 8.20 (1H, s), 6.09 (1H, d, J = 6.5 Hz), 4.22–4.10 (1H, 
m), 3.81–3.70 (1H, m), 3.48 (1H, dd, J = 9.8, 4.8 Hz), 3.37 (2H, t, J = 6.6 
Hz), 3.25 (2H, t, J = 6.3 Hz), 2.97–2.87 (2H, m), 2.74–2.68 (1H, m), 2.34 
(2H, t, J = 6.5 Hz), 1.39–1.29 (2H, m), 1.21–1.09 (10H, m), 1.06 (3H, d, J = 
6.9 Hz, CHCH3), 0.81 (3H, s), 0.74 (3H, t, J = 7.1 Hz, CH2CH3), 0.68 (3H, 
s); ESI-MS m/z [M−2H]2− 474.6217 (C32H54N7O18P3S requires 474.6229). 
 
 
4.16. Evaluation of inhibition of AMACR by test compounds 
 
Colorimetric assays were performed as previously described [32]. Dose 
response curves were used to determine IC50 values for inhibitors. Enzyme (4 
× stock, 150 µL) and inhibitor at the appropriate con-centration (4 × stock, 
150 µL) were incubated together in 96 well plates at ambient room 
temperature for 10 min. The sample was divided into three repeats of 100 µL 
before addition of substrate (2 × stock, 3 × 100 µL; final concentration of 40 
μM in the assay) and monitored at 354 nm. Each 200 µL assay contained ca. 
8 µg of total AMACR protein (0.85 µM, assuming a molecular weight of 
47,146.8 Da. with one active site per monomer [7]). Final concentrations of 
inhibitor in the assay were 100, 33.3, 11.1, 3.7, 1.23, 0.411, 0.137 and 0.045 
µM unless otherwise stated. Positive controls contained enzyme and substrate 
1 only and negative controls buffer and substrate. Rates in Absorban-ce.min−1 
were determined using Excel and converted to nmol.-min.−1mg−1 using the 
2,4-dinitrophenoxide 2 extinction coefficient (15,300 M−1 cm−1) [32] with 
the path-length (0.588 cm) determined by the plate-reader. IC50 values were 
determined using reaction rate, with the data fitted to a 4-parameter logistic 
using SigmaPlot 13 using Log10 inhibitor concentration (in μM). In some 
cases 2–3% (v/v) DMSO was included in assays; no significant change in 
enzyme activity was observed with DMSO concentrations of up to 8% (v/v) 
[32]. Half-vo-lume 96 well plates were used for some inhibitors; identical 
IC50 values were obtained for standard inhibitors using both types of 
microtitre plate. IC50 values [32] for N-dodecyl-N-methylcarbamoyl-CoA 4 
and ibuprofenoyl-CoA 5 were determined contemporaneously with the in-
hibitors described in this study, with the same batch of enzyme. 
 
 
  
4.17. Computational analysis of potency of inhibition 
 
Lipophilicity of acyl-CoA esters was assessed by calculation of miLogP 
values using the molecular properties calculator (http://www. 
molinspiration.com/cgi-bin/properties). miLogP values were calculated using 
molecular smiles obtained from Chemdraw Professional 15. IC50 values (in 
nM) were plotted against the obtained LogP value using SigmaPlot 13. 
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